Key Takeaways:
- Meiogenix, a biotechnology company focused on precision breeding for crop improvement, has appointed Jacqueline Heard, Ph.D., MBA to its Board of Directors.
- Heard most recently founded and led Enko Chem, and previously held senior roles at Monsanto, Flagship Pioneering, CiBO Technologies, Two Blades Foundation, and Mendel Biotechnology.
- The appointment comes as Meiogenix advances commercialisation and partnership development around its targeted recombination platform.
- Heard joins an existing board that includes Neal Gutterson, Jenny Rooke, Michael Krel, Benoit Barteau, and Ricardo Garcia de Alba.
- No financial terms or structural changes to the company were disclosed alongside the announcement.
Meiogenix Names Jacqueline Heard to Its Board of Directors
Biotechnology company Meiogenix announced on 13 April 2026 the appointment of Jacqueline Heard, Ph.D., MBA to its Board of Directors. The company, based in Research Triangle Park, North Carolina, is focused on precision breeding technologies designed to expand access to natural genetic diversity in crops.
The appointment comes as Meiogenix works to advance commercialisation efforts and build partnerships around its targeted recombination platform.
Heard's Professional Background
Heard has held a range of senior roles across the agricultural and biotechnology sectors. Most recently, she founded and led Enko Chem, a crop protection company that developed an AI-enabled discovery platform for agricultural chemistries. Prior to that, she held leadership positions at Monsanto, Two Blades Foundation, CiBO Technologies, Flagship Pioneering, and Mendel Biotechnology.
